Hereditary Genetic Changes and Somatic Mutations in Precision Oncology-Recorded Webinar

Video Transcription

Video Summary

The Florida Society of Pathologists hosted a Precision Medicine Academy lecture on hereditary genetic changes and somatic mutations in oncology, featuring Dr. Marilyn Bui, Dr. Terry Boyle, and Dr. Christine Wackel. The lecture was held on their new FSP Learning Center platform and offered CME credits with support from AstraZeneca and Dianqi Senko. The series aims to enhance understanding of precision medicine topics such as molecular diagnostics and personalized treatment strategies. Dr. Boyle and Dr. Wackel discussed the differences between germline and somatic variants and their implications in cancer treatment, highlighting the role of genetic profiling in guiding therapeutic decisions. They explained the importance of understanding the hereditary vs. acquired nature of mutations and the integration of molecular pathology in patient care.<br /><br />The session included a case study on a patient with ovarian cancer, illustrating the use of BRCA mutations and loss of heterozygosity scores in assessing treatment options with PARP inhibitors. The speakers emphasized that while somatic tests can indicate potential germline mutations, these require validation through dedicated germline testing. Additionally, they discussed how new technologies like RNA-based NGS are useful in capturing genetic alterations like fusions and splice variants.<br /><br />The lecture also touched on the future of genomic testing and the challenges in standardizing homologous recombination deficiency (HRD) assessments, impacting the application of targeted therapies across multiple cancer types. The event concluded with an overview of forthcoming educational programs and a reminder for participants to utilize the FSP Learning Center for ongoing professional development.

Keywords

Florida Society of Pathologists

Precision Medicine Academy

germline vs somatic mutations

molecular diagnostics

genetic profiling in oncology

BRCA mutations

PARP inhibitors

loss of heterozygosity (LOH) score

RNA-based next-generation sequencing (NGS)

homologous recombination deficiency (HRD) testing